Slide 1: Company Presentation
Company Presentation May 2026 AIM: POLB
Slide 2: Disclaimer
Disclaimer The contents of this presentation and the information which you are given at the time of the presentation have not been approved by an authorised person within the meaning of the Financial Services and Markets Act 2000 (the “Act”). Reliance on this presentation for the purpose of engaging
Slide 3: Investment Case
Investment Case Partnering Focused Model 1 Experienced team with proven track record of closing significant transactions / exits High value programmes with strong IP A clinical-stage company developing POLB 001 which has High value clinical-stage programmes Proof-of-concept the potential to transfor
Slide 4: FY25: A Transformative Year for Poolbeg
FY25: A Transformative Year for Poolbeg Building towards clinical data and partnering CASH FUNDRAISE POLB 001 MARKET OPPORTUNITY £7.7m £4.865m >US$10bn As at 31 December 2025 June 2025 Multi-billion-dollar peak sales potential Funded through near-term clinical milestones Oversubscribed & upsized TOP
Slide 5: 2026 – Strong Progress & Key Data Imminent
2026 – Strong Progress & Key Data Imminent Building towards clinical data and partnering Major patent grant MHRA approval First national grant within Poolbeg’s cancer immunotherapy-induced All regulatory approvals received for TOPICAL trial CRS patent family Peer-reviewed data published Multi-billio
Slide 6: High Value Pipeline Programmes
High Value Pipeline Programmes Multiple near-term clinical value inflection points – positioned well for partnering Product Modality Indication Preclinical Phase 1 Phase 2 Phase 3 Key Milestones TOPICAL trial in multiple myeloma patients Cancer POLB 001 p38 MAPK Immunotherapy- FDA Orphan Teclist
Slide 7: POLB 001 – potential first approved preventative therapy for cancer immunotherapy-induced CRS
POLB 001 – potential first approved preventative therapy for cancer immunotherapy-induced Cytokine Release Syndrome (CRS) POLB 001 has the potential to transform the cancer immunotherapy field through the prevention of CRS thereby expanding administration of cancer immunotherapies from centralised s
Slide 8: Changing Landscapes & the Role of Bispecific Antibodies
Changing Landscapes & the Role of Bispecific Antibodies A cornerstone of next generation immunotherapies Myeloma Patient 1 Myeloma Patient 2 Bispecific antibodies Diagnosed 2003 Diagnosed 2026 Breakthrough immunotherapy with immense benefits across a growing range of cancers Treatment Options Treatm
Slide 9: Illustrative: How POLB Could Make Cancer Immunotherapy Safer
Illustrative: How POLB 001 Could Make Cancer Immunotherapy Safer Transforming cancer care for patients and healthcare systems Patient 1 Current Standard of Care Patient 2 Utilising POLB 001 Immunotherapy activates the Patient takes POLB 001 before 1 immune system to fight cancer 1 treatment Immunoth
Slide 10: POLB 001: Executive Summary
POLB 001: Executive Summary Potential to make immunotherapies safer and more accessible p38 MAPK INHIBITOR STRONG PRECLINICAL & CLINICAL DATA SIGNIFICANT MARKET OPPORTUNITY • Selectively prevents excessive • Favourable safety and tolerability • >US$10B market opportunity1 inflammation without profil
Slide 11: Phase 1b LPS Human Challenge – Potent Inhibition of Excessive Inflammation
Phase 1b LPS Human Challenge – Potent Inhibition of Excessive Inflammation ASH ‘23 Positive data supports the potential of POLB 001 to effectively prevent CRS Phase 1b LPS Human Challenge Trial IL-6 Levels IL-8 levels • Excellent safety & tolerability profile • Potent target inhibition confirmed • C
Slide 12: POLB 001 First-in-Patient TOPICAL Trial
POLB 001 First-in-Patient TOPICAL Trial J&J supplying approved bispecific antibody teclistamab TOPICAL - Trial of Prevention of ImmunoCytokine Adverse events in Myeloma Leading Cancer Chief Investigator Dr Emma Searle, MBChB MA MRCP FRCPath PhD Research Centres Trial run by Accelerating Clinical Tri
Slide 13: POLB 001 First-in-Patient TOPICAL Trial
POLB 001 First-in-Patient TOPICAL Trial Trial designed to produce rapid & compelling data for the effectiveness of POLB 001 to prevent CRS Trial Design Milestones BsAb BsAb First Tx Weekly Supply of approved teclistamab secured from Dose 1 Dose 2 Dose BsAb Dosing J&J at no cost to Poolbeg Protoc
Slide 14: The RISE Programme: Academic & Industry Validation
The RISE Programme: Academic & Industry Validation Poolbeg as lead industry partner in a groundbreaking CRS research programme ABOUT RISE PROGRAMME PARTNERS LED BY R educing University of Manchester – programme lead Dr Jonathan Lim The Christie NHS Trust – clinical lead Clinical Senior Lecturer & I
Slide 15: Prophylactic treatment of CRS represents a significant market opportunity
Prophylactic treatment of CRS represents a significant market opportunity in excess of US$10bn A significant opportunity exists for CRS prophylaxis as adjunct therapy to BsAb and CAR-T treatment AVERAGE COST OF CAR-T AVERAGE COST OF BsAb THERAPY (2025)1 THERAPY (2025)2 • 1st, 2nd and 3rd line+ MM an
Slide 16: Independent Payer Research Covering ~75M Lives
Independent Payer Research Covering ~75M Lives Across Commercial Insurance, Medicare & Medicaid "This research validates both the scale of that unmet need and the appetite among payers for an effective preventative approach. We observed a willingness to pay at commercially meaningful price Multi-bil
Slide 17: Significant Market Opportunity
Significant Market Opportunity Potential to greatly enhance uptake and access to BsAb and CAR-T therapies ~500,000 Patients Bottleneck* An effective CRS through 2030 preventative therapy may remove the bottleneck CRS Eligible bispecific antibody / CAR T >US$10B2 patients in US & EU5 for DLBCL and MM
Slide 18: Partnering Focussed
Partnering Focussed Effective preventative therapy represents a >US$10B market opportunity Pharma Seeking Assets Key Conference Attendance Discussions Ongoing • Growing number of CRS - • JPM Week, Jan 26 • Approved bispecific antibody inducing cancer teclistamab secured from J&J • BIO Europe, Mar 26
Slide 19: GLP-1 Programme
GLP-1 Programme Oral encapsulated GLP-1R agonist targeting the obesity market 19
Slide 20: GLP-1 Market Oral GLP-1
GLP-1 Market Oral GLP-1 A differentiated approach US$20.2 billion • Generally Recognised as Safe (GRAS) oral encapsulation 2025 marked a record year for technology encapsulates an approved GLP-1 receptor agonist obesity and diabetes deal-making1 • Directing GLP-1 receptor agonist to a specific area
Slide 21: Proof of Concept Trial Expected to Commence H2 2026
Proof of Concept Trial Expected to Commence H2 2026 Successful results from the trial may support partnering & multiple opportunities for value creation Trial Investigator: Prof Carel le Roux Site: University of Ulster Objective: Demonstrate GLP-1 uptake The study has been designed to complete quick
Slide 22: Investment Highlights
Investment Highlights Experienced High value clinical- Financial runway Partnering focused team with proven stage programmes into 2027, Strong potential to track record of closing supporting near- secure partnerships targeting critical significant term clinical value based on positive data unmet med
Slide 23: Appendix
POOLBEG PHARMA Appendix
Slide 24: Leadership Team with Record of Delivering Value
Leadership Team with Record of Delivering Value Track record of building successful life-science companies Cathal Friel Jeremy Skillington PhD Ian O’Connell Liam Tremble Executive Chairman Chief Executive Officer Chief Financial Officer Principal Scientist 24
Slide 25: Board Includes Leading Non-Executive Directors
Board Includes Leading Non-Executive Directors A long history of success in the life sciences industry Prof Luke O’Neill Eddie Gibson Prof Brendan Buckley Non-Executive Director Non-Executive Director Non-Executive Director Co-Founder Inflazome which was acquired Market access expert Former Ch
Slide 26: Inhibition of p38 MAPK – A Differentiated Solution For CRS
Inhibition of p38 MAPK – A Differentiated Solution For CRS Mechanism of action • p38 MAPK acts as a gatekeeper to inflammatory responses • Inhibition causes a potent decrease of a wide range of pro- inflammatory cytokines without ablating the immune system POLB 001: Broader Cytokine Inhibition Profi
Slide 27: An Oral p38 MAPK Inhibitor That Selectively Targets Key Inflammatory Pathway
POLB 001 An Oral p38 MAPK Inhibitor That Selectively Targets Key Inflammatory Pathway Without Broad Immunosuppression Phase 2 ready asset with a comprehensive pre-clinical and clinical data package Favourable Safety and Tolerability Profile Designed to Prevent Immunotherapy-Induced CRS 97 subjects d
Slide 28: Potent and Selective Inhibition of p38 MAPK Signalling
POLB 001 Potent and Selective Inhibition of p38 MAPK Signalling Effective target engagement demonstrated in LPS human challenge trial Levels of Phosphorylated p38 MAPK in Circulating Monocytes • POLB 001 was widely distributed • POLB 001 inhibited p38 MAPK activation, direct measurement of activatio
Slide 29: Reduced Key Inflammatory Cytokines Following LPS Challenge
POLB 001 Reduced Key Inflammatory Cytokines Following LPS Challenge Dose dependent reductions, without ablation of immune function TNF-α IL-8 Placebo 30 mg POLB 001 70 mg POLB 001 150 mg POLB 001 TNF-α reduction of 73.5% and 56.2% seen for IL-8 reduction of 80.7% and 76.7% seen for 70 mg and 150 mg
Slide 30: Reduced Key Indicators of LPS-Induced Systemic Inflammation
POLB 001 Reduced Key Indicators of LPS-Induced Systemic Inflammation The reduction of systemic cytokines aligns with improvement in clinically meaningful endpoints Mean Body Temperature Heart Rate Rise (bpm) C-Reactive Protein (CRP) Placebo 30 mg POLB 001 70 mg POLB 001 150 mg POLB 001 No significan
Slide 31: Grades & Severity of CRS
POLB 001 Grades & Severity of CRS CRS is a common adverse event following CAR T and bispecific antibody treatment CRS Parameter1 Grade 1 Grade 2 Grade 3 Grade 4 Fever Fever ≥ 38°C (not attributable to any other cause). In patients who have CRS then receive antipyretics or anti- cytokine therapy such
Slide 32: POLB 001: Flu & Hypercytokinemia - Regulatory Exclusivity / Patent Timeline
POLB 001 POLB 001: Flu & Hypercytokinemia - Regulatory Exclusivity / Patent Timeline Market Exclusivity – 11 years Orphan exclusivity* – 10 years Europe Medical use protection for class of p38 inhibitors – patent granted, further application pending Market Exclusivity – 5 years Orphan Exclusivity* –
Slide 33: Oral Encapsulated GLP-1 - Regulatory Exclusivity / Patent Timeline
Oral Encapsulated GLP-1 Oral Encapsulated GLP-1 - Regulatory Exclusivity / Patent Timeline Exclusively in-licensed rights – patents granted and further applications pending †* Europe Potential for new patent applications to extend term** Exclusively in-licensed rights – patent granted and further ap
Slide 34: Human Challenge Data has Attracted Expert AI Collaborators
Human Challenge Data has Attracted Expert AI Collaborators Novel influenza drug targets successfully identified and Successfully identified drugs with potential to combat RSV prioritised with existing clinical data in other indications CytoReason’s Partners OneThree Biotech’s Partners “Human challen
Slide 35: Stay in touch
POLB 001 has the potential to transform the cancer immunotherapy field through the prevention of CRS thereby expanding administration of cancer immunotherapies from centralised Stay in touch specialist cancer centres into community hospitals Listed on the London Stock Exchange Ticker: POLB Register